Abstract
Alzheimer’s disease (AD) is the most common form of dementia, with cerebrospinal fluid (CSF) β-amyloid (Aβ), total Tau, and phosphorylated Tau providing the most sensitive and specific biomarkers for diagnosis. However, these diagnostic biomarkers do not reflect the complex changes in AD brain beyond plaque and tangle pathologies. Here we report a sensitive, quantitative, and scalable targeted proteomics assay of AD biomarkers representing mainly neuronal, glial, vasculature and metabolic pathways. As quality controls (QCs), we pooled CSF from individuals having normal Aβ and Tau levels (AT-), and individuals having low Aβ and high Tau levels (AT+) to determine the coefficient of variation (CV) and fold-change of protein measurements. Additionally, we analyzed 390 CSF samples using selective reaction monitoring-based mass spectrometry (SRM-MS). Following trypsin digestion, 133 controls (cognitively normal and AT-), 127 asymptomatic (cognitively normal and AT+) and 130 symptomatic AD (cognitively impaired and AT+), and 30 pooled CSF samples were analyzed by SRM-MS using a 15-minute targeted liquid chromatography-mass spectrometry method. Isotopically labeled peptide standards were added for relative quantification by reporting the area ratios for each targeted peptide. We reproducibly detected 62 peptides from 51 proteins in all clinical samples with an average CV of approximately 13% across pools. Proteins that could best distinguish AsymAD and AD cases from controls included SMOC1, GDA, 14-3-3 proteins, and proteins involved in glucose metabolism. In contrast, proteins that could best distinguish AD from AsymAD were mainly neuronal/synaptic proteins including VGF, NPTX2, NPTXR, and SCG2. Collectively, this highlights the utility of high-throughput SRM-MS to quantify peptide biomarkers in CSF that can potentially monitor disease progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the following National Institutes of Health funding mechanisms: U01AG061357 (A.I.L and N.T.S), R01AG070937-01 (J.J.L) and P30AG066511 (A.I.L).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) at Emory University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw mass spectrometry and pre- and post- processed peptide abundance data can be found at https://www.synapse.org/#!Synapse:syn34054965. The results published here are in whole or in part based on data obtained from the AMP-AD Knowledge Portal (https://adknowledgeportal.synapse.org) by the AMP-AD Target Discovery Program and other programs supported by the National Institute on Aging to enable open-science practices and accelerate translational learning.
